Abstract
Gastrointestinal bleeding and perforation, platelet inhibition with altered haemostasis, and renal impairment are among the list of adverse effects associated with the administration of ketorolac. The incidence of serious adverse events has declined since dosage guidelines were revised. Most of the published literature suggests that the overall risk of gastrointestinal or operative site bleeding related to ketorolac therapy is only slightly higher than with opioids. The risk for adverse events, however, increases with high doses, with prolonged therapy (>5 days) or in vulnerable patients (e.g. the elderly). Acute renal failure has been reported after ketorolac treatment but is usually reversible after discontinuation of the drug. As with other nonsteroidal anti-inflammatory drugs (NSAIDs), ketorolac may trigger allergic or hypersensitivity reactions.
Careful patient selection is essential if use of ketorolac is considered. Contraindications to ketorolac use include a history of, or current risk of, gastrointestinal bleeding, risk of renal failure, compromised haemostasis, hypersensitivity to aspirin (acetylsalicylic acid) or other NSAIDs, labour, delivery and nursing. Ketorolac should be prescribed at the lowest dosage necessary to control pain; the duration of therapy should also be limited to as few days as possible. Practitioners should be familiar with, and follow, label warnings and dosage guidelines.
Similar content being viewed by others
References
Council of International Organizations of Medical Sciences. Final report of CIOMS Working Group II. International reporting of periodic drug-safety update summaries. Geneva: Council of International Organizations of Medical Sciences, World Health Organization, 1992
Lewis S. Ketorolac in Europe [letter]. Lancet 1994; 343: 784
Gillis JC, Brogden RN. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53: 139–88
Anonymous. New ketorolac dosage recommendations. Pharm J 1993; 251: 49
Ketorolac: restrictions on parenteral dosage, WHO Drug Info 1993; 7 (2): 64
Bruno JJ, Yang D, Taylor LA. Differing effects of ticlopidine and two prostaglandins synthetase inhibitors on maximum rate of ADP-induce aggregation [abstract]. Thromb Haemost 1981; 46: 412
Antiplatelet Trialists’Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106
Greer IA. Effects of ketorolac tromethamine on hemostasis. Pharmacotherapy 1990; 10(6): 71S–6S
Conrad KA, Fagan TC, Mackie MJ, et al. Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther 1988; 43: 542–6
Concannon MJ, Meng L, Welsh CF, et al. Inhibition of perioperative platelet aggregation using toradol (ketorolac). Ann Plast Surg 1993; 30(3): 264–6
Thwaites BK, Nigus D, Bouska GW, et al. Intravenous ketorolac tromethamine worsened platelet function during knee arthroscopy under spinal anesthesia. Anesth Analg 1996; 82: 1176–81
Thwaites BK, Nigus D, Bouska GW, et al. Intravenous ketorolac tromethamine does not worsen platelet function during knee arthroscopy under general anesthesia. Anesth Analg 1995; 81: 119–24
Weale AE, Durant N, Warwick DJ, et al. Is there a clinical interaction between low molecular weight heparin and nonsteroidal analgesics after total hip replacement? Ann R Coll Surg Engl 1995; 77: 35–7
Koh SCL, Pua HL, Tay DHB, et al. The effects of gynaecological surgery on coagulation activation, fibrinolysis and fibrinolytic inhibitor in patients with and without ketorolac infusion. Thromb Res 1995; 79: 501–14
Varrasi G, Panella L, Piroli A. The effects of perioperative ketorolac infusion on postoperative pain and endocrine-metabolic response. Anesth Analg 1994; 78: 514–9
Watcha MF, Ramirez-Ruiz M, White PF, et al. Perioperative effects of ketorolac and acetaminophen in children undergoing bilateral myringotomy. Can J Anaesth 1992; 39: 649–54
Watcha MF, Barry Jones M, Lagueruela RG, et al. Comparison of ketorolac and morphine as adjuvants during pediatric surgery. Anesthesiology 1992; 76: 368–72
Munro HM, Riegger LQ, Reynolds PI, et al. Comparison of the analgesic and emetic properties of ketorolac and morphine for paediatric outpatient strabismus surgery. Br J Anaesth 1994; 72: 624–8
Hall SC. Tonsillectomies, ketorolac, and the march of progress. Can J Anaesth 1996; 436: 544–8
Gunter JB, Varughese AM, Harrington JF, et al. Recovery and complications after tonsillectomy in children: a comparison of ketorolac and morphine. Anesth Analg 1995; 81: 1136–41
Judkins JH, Dray TG, Hubbell RN. Intraoperative ketorolac and posttonsillectomy bleeding. Arch Otolaryngol Head Neck Surg 1996; 112: 937–40
Splinter WM, Rhine EJ, Roberts DW, et al. Preoperative ketorolac increases bleeding after tonsillectomy in children. An J Anaesth 1996; 43; 6: 560–3
Bailey R, Sinha C, Burgess PA. Ketorolac tromethamine and hemorrhage in tonsillectomy: a prospective, randomized, doubleblind study. Laryngoscope 1997; 107: 166–9
Gallagher JE, Blauth J, Fornadley JA. Perioperative ketorolac tromethamine and postoperative hemorrhage in cases of tonsillectomy and adenoidectomy. Laryngoscope 1995; 105: 606–9
Sutters KA, Levine JD, Dibble S, et al. Analgesic efficacy and safety of single-dose intramuscular ketorolac for postoperative pain management in children following tonsillectomy. Pain 1995; 16: 145–53
Toradol package insert. Nutley, (NJ): Hoffman LaRoche, 1995
Buck M. Clinical experience with ketorolac in children. Ann Pharmacother 1994; 28: 1009–13
Rømsing J, Walther-Larsen S. Peri-operative use of nonsteroidal anti-inflammatory drugs in children: analgesic efficacy and bleeding. Anaesthesia 1997; 52: 673–83
Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. JAMA 1996 Feb; 275; 5: 376–82
Kehlet H, Dahl JB. Are perioperative nonsteroidal anti-inflammatory drugs ulceragenic in the short term? Drugs 1992; 44Suppl. 5: S38–S41
Vane JR, Botting RM. The mode of action of anti-inflammatory drugs. Postgrad Med J 1990; 66Suppl. 4: S2–S17
Bjaranason I, Thjodleifsson B. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Rheumatology (Oxford) 1999; 38Suppl. 1: 24–32
Fosslein E. Adverse effect of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28(2): 67–81
Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 12: 33–9
Traversa G, Walker AM, Ippolito FM, et al. Gastroduodenal toxicity of different anti-inflammatory drugs. Epidemiology 1995; 6(1): 49–54
Menniti-Ippolito F, Maggini M, Raschetti R, et al. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy. Eur J Clin Pharmacol 1998; 54(5): 393–7
Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563–6
Garcia Rodriguez LA, Jick H. The risk of upper gastrointestinal bleeding and/or perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 769–72
Cummings DM, Amadio P. A review of selected newer nonsteroidal anti-inflammatory drugs. Am Family Physician 1994 Apr; 49; 5: 1197–202
Kenny GN. Potential renal, haematological and allergic adverse effects associated with nonsteroidal anti-inflammatory drugs. Drugs 1992; 44Suppl. 5: S31–S6
Murray MD, Brater DC. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med 1990; 112(8): 559–60
Henrich WL, Agodoa LE, Barrett B, et al. National Kidney Foundation Position Paper: analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996; 27: 162–5
DuBose Jr TD, Molony DA, Verani R, et al. Nephrotoxicity of non-steroidal anti-inflammatory drugs. Lancet 1994; 344: 515–8
Aitken HA, Burns JW, McArdle CS, et al. Effects of ketorolac trometamol on renal function. Br J Anaesth 1992; 68: 481–5
Ready LB, Bown CR, Stahigren LH, et al. Evaluation of intravenous ketorolac administered by bolus or infusion for treatment of postoperative pain. Adouble-blind, placebo-controlled, multicenter study. Anesthesiology 1994; 80: 1277–86
Rao TRK, Naidu MUR, Shobha JC, et al. Renal effects of oral ketorolac in patients with mild to moderate pain. Clin Drug Invest 1995; 9: 111–5
Myles PS, Power I. Does ketorolac cause postoperative renal failure: how do we assess the evidence? Br J Anaesth 1998; 80: 420–1
Feldman HL, Kinman JL, Berlin JA, et al. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med 1997; 126: 193–9
Sackett DL, Haynes RB, Guyatt GH, et al. Clinical epidemiology: a basic science for clinical medicine, 2nd ed. Boston: Little Brown, 1991: 283–302
Szezeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975; 1: 67–9
Szezeklik A. aspirin-induced asthma: new insights into pathogenesis and clinical presentation of drug intolerance. Int Arch Allergy Immunol 1989; 90: 70–5
Piado C, Castillo JA, Montserrat JM, et al. Aspirin intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J 1989; 2: 127–9
Szezeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977; 60: 276–84
Hebert WG, Scopelitis E. Ketorolac-precipitated asthma. South Med J 1994; 87; 2: 282–3
Vicks SD, Dean RJ, Tenholder MF. Ketorolac induced respiratory failure in an aspirin sensitive asthmatic. Immunol Allergy Pract 1991; 13: 23–5
Dias MA, Biedlingmaier JF. Ketorolac-induced status asthmaticus after endoscopic sinus surgery in a patient with Samter’s triad. Arch Otolaryngol Head Neck Surg 1997; 117: S176–S8
Zikowski D, Hord AH, Haddox JD. Ketorolac-induced bronchospasm. Anesth Analg 1993; 76: 417–9
Haddow GR, Riley E, Isaacs R, et al. Ketorolac, nasal polyposis, and bronchial asthma: a cause for concern. Anesth Analg 1993; 76: 420–2
Hammonds WD, Donnigan D. Problems in anesthesia: clinical use of ketorolac tromethamine 1993; 3: 268–80
Litvak KM, McEvoy GK. Ketorolac: an injectable non-narcotic analgesic. Clin Pharm 1990; 9(12): 912–35
Hennesey S, Kinman JL, Berlin JA, et al. Lack of hepatotoxic effects of parenteral ketorolac in the hospital setting. Arch Intern Med 1997; 157: 2510–4
Walker JJ, Johnstone J, Lloyd J, et al. The transfer of ketorolac tromethamine from maternal to foetal blood. Eur J Pharmacol 1988; 3495: 509–11
Greer IA, Johnstone J, Tulloch I, et al. Effect of maternal ketorolac administration on platelet function in the newborn. Eur J Obstet Gynecol Reprod Biol 1988; 29(4): 257–60
Diemunsch P, Alt M, Diemunsch AM, et al. Post cesarean analgesia with ketorolac tromethamine and uterine atonia. Eur J Obstet Gynecol Reprod Biol 1997; 72(2): 205–6
Schorr SJ, Ascarelli MH, Rust OA, et al. A comparative study of ketorolac (Toradol) and magnesium sulfate for arrest of preterm labor. South Med J 1998; 91(11): 1028–32
Ostensen M, Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 1998; 19(5): 389–410
Ostensen M. Nonsteroidal anti-inflammatory drugs during pregnancy. Scand J Rheumatol 1998; 107Suppl.: S128–S32
Schaab KC, Dickinson ET, Setzen G. Acute sensorineural hearing loss following intravenous ketorolac administration. J Emerg Med 1995; 13(4): 509–13
Otti T, Weindel M, Bastani B. Ketorolac induced acute reversible hearing loss in a patient maintained on CAPD. Clin Nephrol 1997; 47; 3: 208–9
Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol 1990; 10: 350–4
Langlois R, Paquette D. Increased serum lithium levels due to ketorolac therapy. Can Med Assoc J 1994; 150(9): 1455–6
Iyer V. Ketorolac (Toradol) induced lithium toxicity. Headache 1994 Jul/Aug: 442–4
British National Formulary. 36th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1998
Summers K, Wilson R. Ketorolac injection: a review of its safety and rational use in day case and major surgery. Pharmaceut Med 1994; 8; 115–34
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reinhart, D.J. Minimising the Adverse Effects of Ketorolac. Drug-Safety 22, 487–497 (2000). https://doi.org/10.2165/00002018-200022060-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200022060-00007